EFFEXOR XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EFFEXOR XR (EFFEXOR XR).
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It potently inhibits the reuptake of serotonin and norepinephrine, and weakly inhibits dopamine reuptake. It has no significant affinity for muscarinic, histaminergic, or alpha1-adrenergic receptors.
| Metabolism | Venlafaxine is extensively metabolized in the liver via CYP2D6 to its active metabolite, O-desmethylvenlafaxine (ODV). Minor pathways include CYP3A4 and CYP2C19. ODV is further metabolized by conjugation and oxidative pathways. Both venlafaxine and ODV are eliminated primarily by renal excretion. |
| Excretion | Renal: approximately 87% as metabolites (including venlafaxine, O-desmethylvenlafaxine, and other minor metabolites) and ≤5% as unchanged drug. Biliary/fecal: minimal (about 2%). |
| Half-life | Venlafaxine: 3-7 hours (short, requires extended-release formulation for once-daily dosing); active metabolite O-desmethylvenlafaxine: 9-13 hours (contributes to overall clinical effect). Steady-state achieved within 3 days. |
| Protein binding | Venlafaxine: 27% bound to plasma proteins; O-desmethylvenlafaxine: 30% bound (primarily to albumin and α1-acid glycoprotein). |
| Volume of Distribution | Venlafaxine: 7.5 L/kg (high, indicating extensive tissue distribution). |
| Bioavailability | Oral (extended-release): approximately 45% (due to first-pass metabolism; absolute bioavailability of immediate-release is ~40-45%). |
| Onset of Action | Oral (extended-release): Clinical improvement in depressive symptoms may begin within 1-2 weeks, but full therapeutic response typically requires 4-8 weeks. |
| Duration of Action | Oral (extended-release): 24 hours (allows once-daily dosing due to extended-release formulation). Tapering is required to avoid withdrawal symptoms. |
| Molecular Weight | 277.4 |
75 mg orally once daily; may increase by 75 mg/day increments every 4-7 days to max 225 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 10-29 mL/min: reduce dose by 25-50%; GFR <10 mL/min: reduce dose by 50% and administer every other day. |
| Liver impairment | Child-Pugh class A or B: reduce dose by 50%; Child-Pugh class C: avoid use or reduce dose by 75% with careful monitoring. |
| Pediatric use | Children 8-17 years: initial 37.5 mg orally once daily for first 4 weeks; then increase to 75 mg once daily based on response; max 225 mg/day. Weight-based: 1.25 mg/kg/day initial, titrate to 2.5 mg/kg/day. Limited data for <8 years. |
| Geriatric use | Initial dose 37.5 mg orally once daily; titrate slowly in 37.5 mg increments every 1-2 weeks; maximum 225 mg/day. Monitor for hyponatremia, QTc prolongation, and bleeding risk. |
| 1st trimester | Risk of spontaneous abortion and major congenital malformations, particularly cardiovascular defects. Use only if clearly needed. |
| 2nd trimester | Potential for preterm birth and low birth weight. Monitor for maternal hypertension and preeclampsia. |
| 3rd trimester | Risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (irritability, feeding difficulty, respiratory distress). |
Clinical note
Comprehensive clinical and safety monograph for EFFEXOR XR (EFFEXOR XR).
| Placental transfer | Venlafaxine crosses the placenta; fetal plasma concentrations are approximately 50-80% of maternal levels. Active transport by placental efflux transporters may reduce fetal exposure but significant transfer occurs. |
| Breastfeeding | Venlafaxine and its active metabolite desvenlafaxine are excreted into breast milk. Infant serum levels are highly variable; some infants may have detectable levels. Monitor infant for sedation, poor feeding, and weight gain. Benefit-risk assessment should consider maternal need and infant vulnerability. |
■ FDA Black Box Warning
EFFEXOR XR is not approved for use in pediatric patients. Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Pooled analyses of short-term placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders showed a greater risk of adverse events representing suicidal behavior or thinking (suicidality) during the first few months of treatment in those receiving antidepressants. The risk of suicidal thinking and behavior was increased in a pooled analysis of short-term placebo-controlled trials in children and adolescents with MDD and other psychiatric disorders. The risk of suicidality was not observed in adults aged 65 and older; it was observed in adults aged 18 to 24. Close supervision of patients starting therapy is required.
| Serious Effects |
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuationKnown hypersensitivity to venlafaxine or any excipientsUncontrolled narrow-angle glaucomaUse within 14 days of linezolid or intravenous methylene blue (MAOI activity)
| Precautions | Suicidality risk: monitor for worsening of depression, suicidal thoughts/behaviors, especially at initiation and dose changes., Serotonin syndrome: risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, triptans, MAOIs)., Hypertension: dose-dependent increase in blood pressure; monitor blood pressure regularly., Activation of mania/hypomania: screen patients for bipolar disorder before treatment., Seizures: use with caution in patients with seizure disorders., Angle-closure glaucoma: may precipitate an acute attack in patients with anatomically narrow angles., Hyponatremia: may occur, especially in elderly or volume-depleted patients., Abnormal bleeding: risk of bleeding events, especially with NSAIDs, aspirin, or anticoagulants., Discontinuation syndrome: gradual taper recommended to avoid withdrawal symptoms., Sexual dysfunction: may cause decreased libido, erectile dysfunction, or delayed ejaculation. |
Loading safety data…
| Lactation Rating | L3 – Moderately Safe |
| Teratogenic Risk | First trimester: Studies suggest a small increased risk of congenital cardiac malformations (primarily ventricular septal defects) with venlafaxine exposure, absolute risk ~2-3%. Second trimester: No specific major malformations reported, but risk of persistent pulmonary hypertension of the newborn (PPHN) may be increased (absolute risk <1%). Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress, jitteriness) in up to 30% of exposed neonates. Paroxetine is considered higher risk; venlafaxine is moderate risk. |
| Fetal Monitoring | Monitor maternal blood pressure (venlafaxine may increase BP), liver function tests, and renal function. In third trimester, monitor for signs of neonatal adaptation syndrome (e.g., respiratory distress, feeding intolerance, jitteriness) in the newborn. Consider fetal echocardiography if first-trimester exposure occurs. Monitor maternal weight gain and nutritional status. |
| Fertility Effects | Venlafaxine may cause sexual dysfunction (delayed ejaculation, anorgasmia, decreased libido) in both men and women, potentially affecting fertility. However, no direct evidence of reduced fertility in humans. Hypothalamic-pituitary axis modulation may impact menstrual cycle regularity and ovulation. Discontinuation should be considered if fertility issues arise, under physician guidance. |
| Food/Dietary | Take with food to reduce nausea and GI upset. Grapefruit and grapefruit juice may increase venlafaxine levels; avoid concurrent use. Alcohol can potentiate CNS depression; avoid alcoholic beverages. |
| Clinical Pearls | Use the lowest effective dose; taper gradually on discontinuation to avoid withdrawal symptoms. Monitor blood pressure, especially at doses above 150 mg/day. Avoid use in patients with uncontrolled hypertension. Do not crush or chew capsules. May cause mydriasis; use caution in patients with increased intraocular pressure or narrow-angle glaucoma. |
| Patient Advice | Take exactly as prescribed, with food to reduce nausea. Swallow capsules whole; do not crush, chew, or dissolve. · Avoid abrupt discontinuation; taper under medical supervision to prevent withdrawal symptoms like dizziness, nausea, headache, and irritability. · Inform your doctor if you experience rash, hives, or swelling; signs of serotonin syndrome (agitation, hallucinations, rapid heart rate); or severe hypertension. · Use caution when driving or operating machinery until you know how Effexor XR affects you, as it may cause drowsiness or dizziness. · Avoid alcohol while taking this medication; it can increase side effects and worsen depression or anxiety. · Report any new or worsening symptoms, including suicidal thoughts, especially during early treatment. |